NanoVibronix Inc (Nasdaq: NAOV), a medical device company headquartered in Elmsford, New York, on Tuesday announced the signing of a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial (RCT) study of UroShield.
This clinical study aims to gather additional evidence supporting NanoVibronix's application to the FDA for permanent clearance of the UroShield device.
The company' proprietary technology, which utilises patented low-intensity surface acoustic wave (SAW) technology, allows for the creation of low-frequency ultrasound waves that can be used for medical applications such as disruption of biofilms and bacterial colonisation, as well as for pain relief.
NanoVibronix's primary products, PainShield and UroShield, are portable devices designed for home use without the need for medical professional assistance.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment